Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

Date

09 Oct 2016

Session

NSCLC, metastatic

Presenters

Roy S. Herbst

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

R.S. Herbst1, P. Baas2, D. Kim3, E. Felip4, J.L. Pérez-Gracia5, J. Han6, J. Molina7, J. Kim8, C. Dubos Arvis9, M.A. Ahn10, M. Majem11, M.J. Fidler12, G. De Castro Jr.13, M. Garrido14, Y. Shentu15, G.M. Lubiniecki16, E.B. Garon17

Author affiliations

  • 1 Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital, Yale School of Medicine, 06520-8032 - New Haven/US
  • 2 Thoracic Oncology, The Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3 Internal Medicine, Seoul National University Hospital, 03080 - Seoul/KR
  • 4 Oncologia Médica, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 5 Oncology, Clinica Universidad de Navarra, Pamplona/ES
  • 6 Center For Lung Cancer, National Cancer Center, Goyang/KR
  • 7 Oncology, Mayo Clinic, Rochester/US
  • 8 Department Of Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-do/KP
  • 9 Department Of Oncology, Centre Francois Baclesse, Caen/FR
  • 10 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR
  • 11 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 12 Internal Medicine, Rush University Medical Center, Chicago/US
  • 13 Oncologia Clínica, ICESP - Instituto do Câncer do Estado de São Paulo, 01246-000 - Sao Paulo/BR
  • 14 Hematology And Medical Oncology, Pontificia Universidad Catolica de Chile-Cancer centre, Santiago/CL
  • 15 Bards, Merck & Co., Inc., Kenilworth/US
  • 16 Oncology Clinical Development, Merck & Co., Inc., Kenilworth/US
  • 17 Medicine, Division Of Hematology/oncology, David Geffen School of Medicine at UCLA, Los Angeles/US
More

Resources

Background

In KEYNOTE-010 (NCT01905657), pembro provided superior OS over doce in patients (pts) with previously treated advanced NSCLC for the co-primary PD-L1 tumor proportion score (TPS) ≥1% and ≥50% populations, with no difference between pembro doses. To better characterize long-term outcomes in KEYNOTE-010, an analysis based on an additional 6 mo of follow-up was performed.

Methods

1034 pts with NSCLC of TPS ≥1% that progressed on ≥2 doses of platinum-doublet chemotherapy were randomized to pembro 2 or 10 mg/kg Q3W or doce 75 mg/m2 Q3W. Crossover upon progression was not permitted until Dec 2015. Response was assessed every 9 wk per RECIST v1.1 by central review. Survival was assessed every 2 mo after study treatment discontinuation. Differences in OS were assessed in the ITT population using the stratified log-rank test.

Results

As of Mar 31, 2016, median follow-up was 19.2 mo and median (range) exposure was 106 d (1-773) for pembro 2 mg/kg, 106 d (1-742) for pembro 10 mg/kg, and 62 d (1-462) for doce. Pembro continued to show superior OS with no difference between doses (Table). 18-mo OS rates were 37% with pembro 2 mg/kg, 43% with pembro 10 mg/kg, and 24% with doce for TPS ≥1% and 46%, 52%, and 24% for TPS ≥50%. ORR was higher with pembro for TPS ≥1% (19% vs 20% vs 10%) and ≥50% (29% vs 32% vs 9%). 60% of pembro and 15% of doce responders, including 65% and 15% with TPS ≥50%, were alive, progression free, and without new anticancer therapy. Treatment-related AE rates remained lower with pembro: 64% vs 67% vs 81% any grade, 13% vs 17% vs 36% grade 3-5.

Conclusions

Superior OS for pembro over doce in pts with previously treated, PD-L1–expressing advanced NSCLC was confirmed with longer follow-up, as was the lack of difference between pembro doses, durability of pembro responses, and, despite longer exposure, a lower rate of treatment-related AEs with pembro. These data support pembro as a standard of care for previously treated, PD-L1–expressing NSCLC.

Clinical trial identification

ClinicalTrials.gov number NCT01905657, originally posted July 18, 2013; EudraCT number 2012-004391-19, originally issued 16-Nov-2012

Pembro 2 mg/kg Pembro 10 mg/kg Doce
TPS ≥1%
Median (95% CI), mo 10.5 (9.6-12.4) 13.6 (11.4-17.3) 8.6 (7.9-9.8)
HR (95% CI)a 0.72 (0.60-0.87) 0.60 (0.50-0.73)
HR (95% CI)b 1.19 (0.98-1.45)
TPS ≥50%
Median (95% CI), mo 15.8 (11.0-26.0) 18.8 (12.3-NR) 8.2 (6.6-10.4)
HR (95% CI)a 0.54 (0.39-0.73) 0.48 (0.35-0.66)
HR (95% CI)b 1.18 (0.84-1.64)

aPembro vs doce. bPembro 2 mg/kg vs 10 mg/kg.

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Disclosure

R.S. Herbst: Served as advisory board member for Merck and has received travel expenses, including accommodations, from Merck. P. Baas: Advisory board member: Merck, BMS, Verastem, Celgene; Research funding and travel expenses: Merck, BMS. E. Felip: Consultant/advisor with honoraria: Boehringer Ingelheim, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene; Speakers' bureau: BMS, Novartis, Roche. J.L. Pérez-Gracia: Speakers' bureau and research funding: Merck. J-H. Kim: Reasearch funding: Roche, Lilly, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck. C. Dubos Arvis: Travel expenses: Novartis, Boehringer. M-J.A. Ahn: Advisory board member: BMS, Ono, MSD, Boehringer Ingelheim, AstraZeneca, Roche G. De Castro Jr.: Advisory board member: MSD, Roche, AstraZeneca; Speakers' bureau: MSD, Roche, AstraZeneca, BMS; Travel expenses: MSD. Y. Shentu, G.M. Lubiniecki: Employment and stock options: Merck & Co., Inc. E.B. Garon: Research funding: AstraZeneca, Boehringer-Ingelheim, BMS, Eli Lilly, Genentech, Merck, Novartis, Pfizer. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings